CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 161 filers reported holding CLOVIS ONCOLOGY INC in Q3 2019. The put-call ratio across all filers is 1.19 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $134,000 | -90.6% | 74,712 | -89.4% | 0.00% | -100.0% |
| Q1 2022 | $1,420,000 | +1793.3% | 703,171 | +4060.8% | 0.00% | – |
| Q3 2021 | $75,000 | -98.2% | 16,900 | -98.4% | 0.00% | -100.0% |
| Q3 2019 | $4,187,000 | +42.3% | 1,065,298 | +438.2% | 0.01% | +40.0% |
| Q2 2019 | $2,943,000 | -68.2% | 197,928 | -46.9% | 0.01% | -66.7% |
| Q1 2019 | $9,248,000 | -19.3% | 372,605 | +168.1% | 0.03% | -26.8% |
| Q3 2017 | $11,454,000 | -66.3% | 139,000 | -61.7% | 0.04% | -66.7% |
| Q2 2017 | $33,980,000 | -4.0% | 362,919 | -34.7% | 0.12% | +3.4% |
| Q1 2017 | $35,386,000 | +3613.1% | 555,773 | +2491.3% | 0.12% | +2875.0% |
| Q4 2016 | $953,000 | -9.8% | 21,448 | -29.0% | 0.00% | -20.0% |
| Q4 2015 | $1,057,000 | -63.0% | 30,200 | -2.9% | 0.01% | -66.7% |
| Q3 2015 | $2,860,000 | +39.2% | 31,100 | +1.4% | 0.02% | +7.1% |
| Q2 2013 | $2,054,000 | – | 30,663 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |